

Human IL 12/23 (Briakinumab) Antibody

HRP

Biosimilar Recombinant Human Monoclonal Antibody

Product Information

Product No.: LT502

Clone: ABT-874

Isotype: AB_2893964

RRID: Human IgG1 λ

Storage: Sterile 2° to 8°C

Product Description

Specificity:

This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Briakinumab. Briakinumab recognizes both human IL12 and IL23 via IL-12/23p40. This product is for research use only.

Antigen Distribution:

IL-12 is produced by dendritic cells, macrophages, neutrophils, and human B-lymphoblastoid cells. IL-23 is mainly secreted by activated dendritic cells, macrophages or monocytes.

Background:

Briakinumab is a human monoclonal antibody targets the p40 subunit shared by interleukins 12 and 23. IL-12 associates with IL-23 α to form the heterodimeric cytokine IL-23. IL-23 is associated with various autoimmune inflammatory diseases, and is particularly highly expressed in psoriasis skin lesions. In addition, IL-23 is suspected to play a role in tumorigenesis. Briakinumab binds to and neutralizes human IL-12 and IL-23 (via their shared p40 subunit) and is being investigated for the treatment of rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis. Anti-Human IL 12/23 (Briakinumab) utilizes the same variable regions from the therapeutic antibody Briakinumab making it ideal for research projects.

Known Reactivity Species:

Human

Expression Host:

HEK-293 Cells

Format:

Horseradish Peroxidase (HRPO)

Immunogen:

This antibody was produced by phage display technology.

Formulation

This Biotinylated antibody is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.

Storage and Stability

This horseradish peroxidase conjugated monoclonal antibody is stable when stored at 2° to 8°C.

Do not freeze

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

410 Axminster Dr, St. Louis, MO 63026

(800) 538-1145

leincoglobal@leinco.com

Applications

Applications and Recommended Usage (Quality Tested By Leinco):

FC The suggested concentration for Briakinumab biosimilar antibody for staining cells in flow cytometry is $\leq 1.0 \mu\text{g}$ per 10^6 cells in a volume of 100 μl . Titration of the reagent is recommended for optimal performance for each application.

ELISA

Other Applications Reported in Literature:

FA

Country of Origin

USA

References

- 1) Vsn, M. et al. (2016) VALUE IN HEALTH 19 PSS5:A123